

Global Monkeypox Outbreak Response

WHO EPI-WIN webinar on travel and tourism

5 October 2022


Dr. Rosamund Lewis

WHO Technical Lead Monkeypox Response

Head WHO Smallpox Secretariat



World Health
Organization




WHO Director General declares monkeypox to be a Public Health Emergency of International Concern (PHEIC)

23 July 2022


- The outbreak has met all IHR criteria:
 - be considered extraordinary
 - constitute a public health risk to other states through spread of disease
 - require a coordinated international response
- Unprecedented and rapid spread to many new countries with a clear risk of further international spread
- New/previously unrecognized modes of transmission reported
- Atypical presentation
- **3rd Emergency Committee meeting to be held on 20 October 2022**

Current global epidemiological situation

- 1 Jan - 30 Sept 2022
 - **106** Member States/territories across all 6 WHO Regions are reporting cases
 - **68,265** confirmed cases
 - **26** deaths
 - Downward trend overall
 - Thanks to everyone for all your commitment
 - Still concerning situation in many countries



Confirmed cases of Monkeypox
from 1 Jan 2022, as of 27 Sep 22




Regional Epidemic curves


Note different y-axis scales

data as of 30 Sep 2022 17:00 CEST


African Region




Eastern Mediterranean Region




European Region




Region of the Americas



South-East Asia Region



Western Pacific Region



Date of notification


Source: WHO

Monkeypox - Epidemiological Situation

97% men, median age 35 years
 Most commonly reported exposure: sexual activity

Case profiles for case reports with details %	
MSM	89
HIV +	47
Health worker	4
Sexual Transmission	87

[WHO Global Dashboard](#)



Clinical presentation

- Symptoms include:
 - fever
 - swollen lymph nodes
 - typical or atypical rash
- Lesions evolve: macules – papules – vesicles – pustules, then crust over; progress centrifugally, involve head, hands, feet, mouth, genitals
- New clinical features: proctitis, urethritis and urinary retention
- Many cases are without symptoms
- Complications: severe pain, secondary infections, abscesses, blindness, **myocarditis** and encephalitis, and death
- **HIV – immune reconstitution syndrome**

- Atypical presentations:
 - absence of rash in some cases
 - anal pain or bleeding
 - lesions:
 - only a few or a single
 - in the genital or perineal/perianal area only
 - appearing at asynchronous stages of development
 - appearing before onset of fever





Modes of transmission

- **Knowledge of transmission is evolving**
- Person to person contact
 - sexual encounters are most commonly reported
 - face-to-face (such as talking, breathing, singing)
 - skin-to-skin (such as touching, vaginal or anal sex)
 - mouth-to-mouth (such as kissing)
 - mouth-to-skin (such as oral sex)
 - **pre-symptomatic / asymptomatic ??**
- It can also spread through contaminated environments (surfaces, objects and materials touched by someone infectious)
 - Percutaneous injury – health workers, tattoo parlour (Spain)
 - Congregate settings - health facilities, prisons (Nigeria, Chicago)
 - Densely populated areas - refugee camp in Sudan (>120 suspected cases, clade unknown)
- Common exposure **settings** include parties, bars, saunas, sex-on-premises venues, events and other gatherings
 - **Your support needed** to identify settings in order to support further action (risk reduction messages, engagement with managers...)

Most at risk populations

- Majority of cases are male (98%)
- Males between 18-44 years of age continue to be disproportionately affected (78%)
- The majority of cases (95%) have been detected in men who have sex with men (MSM)
- Those who identify as gay, bisexual or other MSM, or those with recent multiple partners
- Among cases with known HIV status, 47% are HIV positive
- Health workers affected, mostly in the community; several through occupational exposure (needle-stick injuries)
- Immunocompromised continue to be vulnerable and should take precautions
- Pregnant women, children - also priority for post-exposure vaccination





WHO Global Response

Objectives

- Stop the outbreak
- Protect the vulnerable
- Reduce zoonotic transmission

Strategic Approach

- Information
- Action
- Evidence
- Equity



Vaccines and Immunizations for monkeypox

- Primary (pre-exposure) preventive vaccination (PPV) is recommended for persons at high risk of exposure:
 - men who have sex with men, others with multiple casual sex partners
 - health workers, clinical laboratory personnel working on monkeypox,
 - Others who may be at high risk
- Post-exposure vaccination (PEPV) is recommended for close contacts of cases
- WHO working closely with manufacturers to expand production capacity and access
- In the past, smallpox vaccine was ~85% effective in preventing monkeypox (DRC, 1986)
- **New data emerging on vaccine effectiveness**



EVIDENCE

- Randomized control trials strongly recommended
- Other proposed Study Designs
 - Randomization during deployment (Brazil, Columbia, South Africa)
 - Ring vaccination (DRC, Nigeria)


Additional Resources



[Multi-country monkeypox outbreak:
External situation reports](#)



[Key facts about Monkeypox](#)



OpenWHO: Monkeypox introduction
[English](#)
[Francais](#)




[WHO website: Monkeypox](#)




OpenWHO: Monkeypox epidemiology,
preparedness and response
[English](#)
[Francais](#)



[Monkeypox Q&A](#)



[Monkeypox outbreak toolbox](#)



[Monkeypox: public health advice
for gay, bisexual and other men
who have sex with men](#)

Thank you

